Welcome to our dedicated page for Raytech Holding SEC filings (Ticker: RAY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Raytech Holding's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Raytech Holding's regulatory disclosures and financial reporting.
Raytech Holding Limited offers 3,149,832 Ordinary Shares at US$1.97 per share in a primary placement under a prospectus supplement. The offering prices total gross proceeds of US$6,217,768 and net proceeds are estimated at US$6,084,660. The prospectus states total Ordinary Shares outstanding before this offering as 2,724,911 and immediately after this offering as 5,874,743. Two purchasers—Fortune Genesis Holdings Limited and WK Frater Holdings Limited—are affiliated with certain directors and large shareholders and will each purchase 999,014 Ordinary Shares at the public offering price; the company relies on the foreign private issuer home country practice exemption instead of Nasdaq shareholder approval. Net proceeds are earmarked for general corporate and working capital purposes, expansion into personal health care electronics and integration/post-closing costs related to the Worry free Group acquisition.
Raytech Holding Ltd director Liu Haoyuan filed an initial statement of beneficial ownership on Form 3. The filing identifies Liu as a director of Raytech but, in the data provided, does not show any reported purchases, sales, or other insider transactions in company securities.
Raytech Holding Limited is shifting its strategy toward services for personal health care electronics, including product design, development, and consultation, led by subsidiary Raytech Innovation Limited. The legacy personal care electrical appliances trading business via Pure Beauty Manufacturing will continue, while Worry Free Group remains the Group’s independent marketing solutions arm.
To support this pivot, Raytech has appointed Mr. Haoyuan Liu as Chairman and Executive Director, effective April 15, 2026, adding fintech, capital markets, and regulatory experience to the leadership team alongside Executive Director Mr. Ching Tim Hoi. The company reported cash and cash equivalents of HK$121.5 million (US$15.6 million) as of September 30, 2025, which it highlights as providing capacity to execute the new strategy. Management is targeting the fast‑growing Asia Pacific wearable medical devices segment, cited at US$12.55 billion in 2025 and projected to reach US$26.83 billion by 2030, and views the new services platform as its main growth engine.
Raytech Holding Limited appointed Mr. Haoyuan Liu as a director and as Chairman of the Board, effective immediately. Former Chairman Mr. Tim Hoi Ching will remain on the Board, and the change is stated not to result from any disagreement over operations, policies, or practices.
Mr. Liu will receive annual cash compensation of $6,000, payable quarterly, under an offer letter, and is party to an indemnity agreement. His background spans fintech operations, family office and hedge fund roles, and capital markets across Hong Kong, Singapore, and the United States. This report is incorporated by reference into Raytech’s effective Form F-3 registration statement.
Raytech Holding Ltd director Li Shihua has filed an initial insider ownership report on Form 3. The filing identifies Li Shihua as a director and shows no reportable stock purchases, sales, option exercises, gifts, or other transactions in the transaction summary data.
Raytech Holding Ltd director FOK Pak Kin Charles has filed an initial Form 3 insider report. The filing lists him as a director, not an officer or ten percent owner, and the provided data shows no reportable transactions or derivative positions.
Raytech Holding Ltd director YUAN Tianfu has filed an initial Form 3, formally registering as an insider of the company. The filing lists him as a director and indicates no reportable purchases, sales, or other insider transactions in the issuer’s securities at this time.
Tao Wang and Yuan Chun Holding Co., Limited filed a Schedule 13D reporting a major increase in their ownership of Raytech Holding Ltd’s ordinary shares. They now beneficially own 262,319 shares, or about 9.6% of the 2,724,911 shares outstanding.
On February 9, 2026, Yuan Chun Holding acquired 182,404 shares in a privately negotiated transaction for US$392,898, funded from working capital. Before this, the reporting persons held 81,279 shares, or 2.98%. On March 13, 2026, Tao Wang sold his 1,364 directly held shares in open-market trades, consolidating ownership through Yuan Chun. The filing states the shares were acquired for investment purposes.
Raytech Holding Ltd filed an initial insider ownership statement for chief finance officer Wan Yee Hing. This Form 3 filing identifies Wan Yee Hing as an officer of the company and establishes their reporting status for future insider transactions. The data provided shows no insider transactions or option exercises reported in this filing.
Raytech Holding Ltd director Wang Shibin filed an initial Form 3 as an insider of the company. The filing does not report any buy or sell transactions and shows no derivative positions or other holdings entries, serving mainly as a baseline disclosure of his insider status.